bkrao
☆    

India,
2015-08-10 09:24
(3970 d 23:23 ago)

Posting: # 15200
Views: 6,843
 

 Randomization access [Regulatives / Guidelines]

Hi,
Is there is any restriction that the bioanalytical department should not be accessable to randomization schedule? If so, please let me know the source guidelines.

My exact intention is whether the person who knows the randomization schedule can be able to perform the bioanalytical activities also? Is there any regulatory violation.?Kindly clarify. If so, then let me know the respective guidance with respect to the same provison.

I hope randomization shcdule must be blinded to the bioanalytical department before bio analysis to avoid the bias.

I egarly awaited for your valubale suggestions.

Thanks & Regards,
Balaga Koteswara Rao.
Cadila Pharmaceuticals Ltd.
BE-proff
●    

2015-08-10 10:38
(3970 d 22:09 ago)

@ bkrao
Posting: # 15201
Views: 5,895
 

 Randomization access

Hi,Balaga

I have seen a lot of reports done by European laboratories.
All of them contain PK and concentration data along with randomization codes :-)
All these labs have been audited and inspected so that they hardy violate anything.
bkrao
☆    

India,
2015-08-10 10:51
(3970 d 21:57 ago)

@ BE-proff
Posting: # 15204
Views: 5,954
 

 Randomization access

Thanks you dear.

My question is whether the treatment randomization is accessable to the bioanalytical persons before the intioation of the bioanalytial phase.

Thanks & Regards,
Balaga Koteswara Rao,
Cadila Pharmaceutical Ltd.
BE-proff
●    

2015-08-10 11:41
(3970 d 21:06 ago)

@ bkrao
Posting: # 15207
Views: 5,888
 

 Randomization access

Hi again,

I think yes but anyway ask a laboratory if randomization info is to be sent before analytical phase (possible compliance with lab SOPs)
ElMaestro
★★★

Denmark,
2015-08-10 11:51
(3970 d 20:57 ago)

@ bkrao
Posting: # 15208
Views: 5,877
 

 Randomization access

Hi bkrao,

❝ My question is whether the treatment randomization is accessable to the bioanalytical persons before the intioation of the bioanalytial phase.


Usually, BE studies are open-label and control of the rand. code is thus not extremely crucial, but it is a good habit in the industry to keep the rand. code away from bioanalysts. Most companies I know of state that bioanalysts are actually kept blind, both in protocols and SOPs. I think this is a very healthy principle but it is not specifically regulated by a guideline.

Pass or fail!
ElMaestro
bkrao
☆    

India,
2015-08-10 12:18
(3970 d 20:29 ago)

@ ElMaestro
Posting: # 15209
Views: 5,908
 

 Randomization access

Thanks you.

I required few more suggestions in this regard.

If analyst knows the treatment received by the subject, then the analysis bias is open thing know?

Then the study will be a result oriented, analyst driven study, we can call. but its should not be actual outcome required by the regulatory i hope, kindly suggest.


Thanks you & Regards,
Balaga Koteswara Rao,
Cadila Pharmaceuticals Ltd.
ElMaestro
★★★

Denmark,
2015-08-10 12:53
(3970 d 19:54 ago)

@ bkrao
Posting: # 15210
Views: 5,830
 

 Result oriented? Analyst driven?

Hi Mr. Rao,

now you sound like a banker or a LEAN consultant :-D
I don't know how those terms fit into the realm of regulated BE.

Why would a bioanalyst have access to the rand. code after all? I think there should be a reason; preferably a better reason than just convenience. Of course, from a regulatory side there might arise a bit of fear that knowledge pf the rand. code could be used inappropriately somehow: As far as I can tell a bioanalyst knowing the rand. code can use that knowledge inappropriately during the analysis phase (without going into detail, mind you), and coversely I don't see how the knowledge can be used in a good fashion. If you ever find yourself in a situation where people question the integrity of a study then you are better off if you can demonstrate that the QMS is mature and that the rand. code is not accessible or accessed until the day of stats.

Pass or fail!
ElMaestro
bkrao
☆    

India,
2015-08-10 15:22
(3970 d 17:25 ago)

@ ElMaestro
Posting: # 15213
Views: 5,850
 

 Result oriented? Analyst driven?

Please respond any one,

Whether the the person who involved in the clinical phase of the study is able to involve in the bioanalytical phase also? If so, then what about the compliance to the treatment blinding condition?
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2015-08-10 20:33
(3970 d 12:15 ago)

@ bkrao
Posting: # 15214
Views: 5,756
 

 Relax

Hi Balaga,

❝ Please respond any one,


Such an “ASAP” attitude sends me into a deep slumber. We are posting in our free time here…

❝ Whether the the person who involved in the clinical phase of the study is able to involve in the bioanalytical phase also? If so, then what about the compliance to the treatment blinding condition?


Can you give an example? A study nurse doing liquid-liquid extraction?

One of my stories. We had to deal with a very sensitive drug and stabilization was a tricky pro­­cedure. We decided not to leave it on the shoulders of the clinical staff but opted for one of our bioanalysts. To avoid troubles with breaking the blind, we also decided that this analyst was not part of the team working in the analytical phase later on. But: You never can proof to an inspector that this guy is not an idiot savant who easily memorizes a three page random list and tell it to his colleagues later. :-D

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
bkrao
☆    

India,
2015-08-11 07:44
(3970 d 01:03 ago)

@ Helmut
Posting: # 15221
Views: 5,739
 

 Thanks you

Really Sorry dear Helmut for the term "ASAP".... i understood your busy schedule.

Thanks a lot for your valuable suggestion.
Ohlbe
★★★

France,
2015-08-17 20:14
(3963 d 12:33 ago)

@ bkrao
Posting: # 15287
Views: 5,544
 

 Randomization access

Dear Balaga,

❝ Is there is any restriction that the bioanalytical department should not be accessable to randomization schedule? If so, please let me know the source guidelines.


EMA BE guideline, § 4.1.7, last line:
Analysis of samples should be conducted without information on treatment.

Regards
Ohlbe
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
144 visitors (0 registered, 144 guests [including 25 identified bots]).
Forum time: 08:48 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5